Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
Bio-Techne Corporation (NASDAQ: TECH) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 4:30 p.m. EST. Chuck Kummeth, CEO, will lead the presentation, which will be available via a live webcast on the company’s Investor Relations page. Bio-Techne specializes in high-quality purified proteins, reagent solutions, and diagnostic products, generating approximately $931 million in net sales in fiscal 2021. The company employs around 2,700 people globally.
Bio-Techne Corporation (NASDAQ: TECH) appointed Brenda Everson as Senior Vice President of Human Resources, effective January 10, 2022. She succeeds Struan Robertson, who is set to retire on February 11, 2022. Everson brings over 20 years of experience, most recently as VP of HR at Midco and previously at Apple, where she held senior roles for 18 years. President Chuck Kummeth praised Robertson's contributions to the company's culture and expressed enthusiasm for Everson's leadership skills as the company continues to grow.
Bio-Techne Corporation (NASDAQ: TECH) has appointed William A. Geist as President of the Protein Sciences Segment, effective January 3, 2022. He replaces N. David Eansor, who is retiring but will assist with the transition until February 2022. Mr. Geist brings over two decades of experience, previously serving as COO at Quanterix and VP at Thermo Fisher Scientific. His expertise in managing life science tool businesses generating over $1 billion in annual revenue positions him well to drive growth in the Protein Sciences Segment.
Bio-Techne Corporation (NASDAQ: TECH) has announced an option agreement with Wilson Wolf Corporation, allowing for a potential 20% ownership stake after Wilson Wolf achieves $100 million in revenue or $50 million in EBITDA. Additionally, Bio-Techne can fully acquire Wilson Wolf upon reaching approximately $225 million in revenue or $135 million in EBITDA. Wilson Wolf specializes in cell culture technologies, particularly the G-Rex® product line, crucial for cell therapy. This partnership aims to enhance cell and gene therapy manufacturing efficiency.
Bio-Techne Corporation (NASDAQ: TECH) announced a significant breakthrough with the publication of a manuscript in Scientific Reports demonstrating their lateral flow technology for COVID-19 diagnostics. The proof-of-concept study shows an affordable test using a minimally invasive swab that yields results in 15 minutes, featuring 87.5% sensitivity and 100% specificity. The company aims to collaborate with diagnostic firms to further develop rapid diagnostic tests leveraging their extensive resources.
Bio-Techne Corporation (NASDAQ: TECH) announced presentations at two investor conferences. Chuck Kummeth, CEO, will speak at the Stephens Annual Investment Conference on December 2, 2021 at 4:00 p.m. CDT. Jim Hippel, CFO, will present at the Evercore ISI HealthCONx Conference on December 1, 2021 at 4:20 p.m. EDT. Both events will have live webcasts accessible through Bio-Techne's Investor Relations website. The company generated approximately $931 million in net sales in fiscal 2021, highlighting its significant role in biomedical research and diagnostics.
ScaleReady has launched the G-Rex®500M-CS, a second-generation product that enhances cell and gene therapy manufacturing. This new device offers a shelf-life extension to three years, improved ergonomics, and various operating options. ScaleReady, a joint venture of Fresenius Kabi and Bio-Techne (NASDAQ: TECH), aims to simplify and automate manufacturing processes, driven by strong growth in the cell therapy market. Josh Ludwig noted the importance of reliable systems in producing high-quality cells, essential for effective therapies.
Bio-Techne Corporation (NASDAQ: TECH) will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 10:00 a.m. EDT. Jim Hippel, the Executive Vice President and CFO, will lead the presentation. A live webcast will be available on Bio-Techne's Investor Relations website.
Bio-Techne specializes in developing high-quality proteins and diagnostic products, generating approximately $931 million in net sales in fiscal 2021. The company employs around 2,700 people globally.
Bio-Techne Corporation (NASDAQ:TECH) announced the launch of the AmplideX® PCR/CE CFTR Kit, designed to detect pathogenic variants in the CFTR gene, which is associated with cystic fibrosis. This new kit offers broader variant coverage for diverse populations, detecting approximately 93% of known pathogenic variants in the U.S. The assay delivers results in under five hours and includes push-button data analysis software. The launch underscores Bio-Techne's commitment to enhancing diagnostic accuracy across all ancestries.
Bio-Techne Corporation (NASDAQ: TECH) announced that its Executive Vice President and CFO, Jim Hippel, will present at the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 11:20 a.m. EST. The presentation will be available via a live webcast on Bio-Techne's Investor Relations website. The company specializes in high-quality purified proteins, reagents, and diagnostic products, generating approximately $931 million in net sales in fiscal 2021. Bio-Techne employs around 2,700 staff globally, focusing on advancing biological research and molecular diagnostics.